Togo
Tuberculosis profile
| High HIV burden |
Population  2012 6.6 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.58 (0.25–1) 8.7 (3.8–15)
Mortality (HIV+TB only) 0.38 (0.31–0.44) 5.8 (4.7–6.6)
Prevalence  (includes HIV+TB) 6.9 (3.4–12) 104 (51–176)
Incidence  (includes HIV+TB) 4.9 (4–5.8) 73 (60–87)
Incidence (HIV+TB only) 1.2 (0.98–1.4) 18 (15–21)
Case detection, all forms (%) 59 (49–71)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 2 112 (78) Relapse 119 (63)
Smear-negative 168 (6) Treatment after failure 36 (19)
Smear-unknown / not done 0 (0) Treatment after default 33 (18)
Extrapulmonary 444 (16) Other 0 (0)
Other 0 (0)      
Total new 2 724   Total retreatment 188  
           
Other (history unknown) 0        
Total new and relapse 2 843   Total cases notified 2 912  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.6    
Age < 15 26    
Laboratories 2012
Smear (per 100 000 population) 1.7
Culture (per 5 million population) 0.8
Drug susceptibility testing (per 5 million population) 0.8
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 85   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 86  
Retreatment 78  
TB/HIV 2012 Number (%)
TB patients with known HIV status 2 657 (91)
HIV-positive TB patients 625 (24)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 541 (87)
HIV-positive TB patients on antiretroviral therapy (ART) 476 (76)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
41 (2–78) 36 (14–58)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 0 (0%) 2 (1%) 2
Laboratory-confirmed MDR-TB cases 0 2 2
Patients started on MDR-TB treatment     2
Financing TB control 2013
National TB programme budget (US$ millions) 1.4
% Funded domestically 24%
% Funded internationally 46%
% Unfunded 31%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data